Literature DB >> 28770275

Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET.

Shinsuke Sasada1,2, Hiroaki Kurihara3, Takayuki Kinoshita4, Masayuki Yoshida5, Natsuki Honda3, Tatsunori Shimoi1, Akihiko Shimomura1, Kan Yonemori1, Chikako Shimizu1, Akinobu Hamada6, Yousuke Kanayama7, Yasuyoshi Watanabe7, Yasuhiro Fujiwara1, Kenji Tamura8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28770275     DOI： 10.1007/s00259-017-3781-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.

Authors:  Kenji Tamura; Hiroaki Kurihara; Kan Yonemori; Hitoshi Tsuda; Junko Suzuki; Yuzuru Kono; Natsuki Honda; Makoto Kodaira; Harukaze Yamamoto; Mayu Yunokawa; Chikako Shimizu; Koki Hasegawa; Yousuke Kanayama; Satoshi Nozaki; Takayuki Kinoshita; Yasuhiro Wada; Shusaku Tazawa; Kazuhiro Takahashi; Yasuyoshi Watanabe; Yasuhiro Fujiwara
Journal:  J Nucl Med       Date:  2013-09-12       Impact factor: 10.057

2.  Molecular phenotype of the foci in multifocal invasive breast carcinomas: intertumoral heterogeneity is related to shorter survival and may influence the choice of therapy.

Authors:  Gyula Pekar; Maria Gere; Miklos Tarjan; Dan Hellberg; Tibor Tot
Journal:  Cancer       Date:  2013-10-11       Impact factor: 6.860

3.  64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.

Authors:  S Sasada; H Kurihara; T Kinoshita; M Yoshida; N Honda; T Shimoi; A Shimomura; M Yunokawa; K Yonemori; C Shimizu; A Hamada; Y Kanayama; Y Watanabe; Y Fujiwara; K Tamura
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

4.  (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.

Authors:  Hiroaki Kurihara; Akinobu Hamada; Masayuki Yoshida; Schuichi Shimma; Jun Hashimoto; Kan Yonemori; Hitomi Tani; Yasuji Miyakita; Yousuke Kanayama; Yasuhiro Wada; Makoto Kodaira; Mayu Yunokawa; Harukaze Yamamoto; Chikako Shimizu; Kazuhiro Takahashi; Yasuyoshi Watanabe; Yasuhiro Fujiwara; Kenji Tamura
Journal:  EJNMMI Res       Date:  2015-03-12       Impact factor: 3.138

5.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544
  5 in total
  3 in total

Review 1.  Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer.

Authors:  Kelly E Henry; Gary A Ulaner; Jason S Lewis
Journal:  PET Clin       Date:  2018-07

Review 2.  Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy.

Authors:  Alberto Signore; Chiara Lauri; Sveva Auletta; Michela Varani; Livia Onofrio; Andor W J M Glaudemans; Francesco Panzuto; Paolo Marchetti
Journal:  Cancers (Basel)       Date:  2020-03-25       Impact factor: 6.639

Review 3.  HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.

Authors:  Betül Altunay; Agnieszka Morgenroth; Mohsen Beheshti; Andreas Vogg; Nicholas C L Wong; Hong Hoi Ting; Hans-Jürgen Biersack; Elmar Stickeler; Felix M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-12       Impact factor: 9.236
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.